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Programmed Death Pathway Inhibition: Emerging Therapeutic
Options for Treatment of Advanced or Refractory Cancers
Katherine Elsass, Morgan Homan, Jana Randolph, Brendan Rasor, David Kinder, BS, M.S., Ph.D.

Abstract
The programmed death-1 (PD-1) pathway has a significant
role in the promotion of immune tolerance. The PD-1 receptor ligands are normally expressed on various inactive immune cells. When cancer cells express these ligands, they are
able to interact with active T and B lymphocytes to induce
this tolerance. Nivolumab and pembrolizumab are two recently approved agents that act to disrupt this binding and
facilitate an immune response against cancer cells. Numerous trials, including KEYNOTE-002 and CheckMate 063, have
demonstrated the superior safety and efficacy of these drugs
in patients with advanced or refractory cancers. Initially
approved for the treatment of advanced or metastatic
melanoma, both nivolumab (Opdivo®) and pembrolizumab
(Keytruda®) have recently received expanded indications for
the treatment of advanced squamous and non-squamous
non-small cell lung cancer (NSCLC). However, both agents
were granted accelerated approval and long-term studies
evaluating their use are ongoing. Adverse drug events commonly associated with PD-1 inhibitors include fatigue, pruritus, decreased appetite and gastrointestinal disorders. More
serious immune-mediated events such as hepatitis, colitis,
hypophysitis, nephritis and thyroid disorders may also occur.
The cost of therapy with anti-PD-1 drugs can reach upwards
of $143,000 to $150,000 per year. Pharmacists should be
familiar with current therapeutic recommendations regarding PD-1 targeted therapy. Pharmacists may also counsel
patients on how to monitor for adverse reactions and common side effects associated with these medications.
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The PD-1 Pathway
The programmed death-1 (PD-1) pathway serves as a protection against immune-mediated damage to healthy tissues,
particularly by promoting T-cell tolerance.1 The PD-1 receptor is located on the extracellular surface of activated T and B
lymphocytes. Two endogenous ligands are known to bind
PD-1 receptors: programmed death-1 ligand 1 (PD-Ll) and
programmed death-1 ligand 2 (PD-L2),2.3 The PD-Ll is expressed by resting T and B lymphocytes, dendritic cells and
macrophages, while PD-L2 expression has been observed
only on dendritic cells and macrophages. Both PD-Ll and PDL2 bind to the same PD-1 receptors located on T and B lymphocytes. Resting cells that express PD-Ll and PD-L2 may
increase extracellular expression of PD-Ll or PD-L2 upon cell
activation. When one of the ligands binds to the PD-1 receptor on T-cells, the resulting interaction inhibits signaling of
T-cell receptors, leading to decreased T -cell proliferation and
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decreased cytokine production, thereby decreasing the immune response.4,5 This pathway is important for promoting
peripheral T-cell tolerance to minimize destruction of
healthy cells.1
Some forms of cancer cells are known to overexpress PD-Ll
or PD-L2, including melanoma cells and carcinoma cells of
the ovary, breast and lung.6 The expression of the ligands PDLl or PD-L2 by cancer cells may contribute to tumor evasion
of the immune system. Anti-PD-1 drugs, including nivolumab
and pembrolizumab, inhibit the PD-1 pathway and allow the
immune system to recognize the cancer cells. 4,5 Inhibition of
the PD-1 pathway represents a new mechanism for anticancer treatment by inhibiting T-cell tolerance and stimulating the body's intrinsic immune responses to kill cancer cells.
Anti-PD-1 Drugs
Therapeutic Indications
The two anti-PD-1 drugs currently approved by the U.S. Food
and Drug Administration (FDA), nivolumab (Opdivo®) and
pembrolizumab (Keytruda®), are fully humanized monoclonal immunoglobulin G4 (IgG4) antibodies. 4.5 Both nivolumab
and pembrolizumab are approved to treat unresectable or
metastatic melanoma in patients who have experienced progression of the disease after treatment with ipilimumab and,
if positive for BRAF V600 mutation, a BRAF inhibitor.4,5,7
Pembrolizumab was approved for melanoma treatment in
September 2014, and nivolumab was approved for advanced
melanoma in December 2014.B,9 On Nov. 24, 2015, the indication of nivolumab was expanded to include its use as a firstline treatment for unresectable or metastatic melanoma in
patients with BRAF V600 wild-type melanoma.10 As a firstline melanoma treatment in these patients, nivolumab may
be used as monotherapy or in combination with ipilimumab.4·7 Both drugs were approved under the FDA's Accelerated Approval Program.s.9 This program fast-tracks
approval for agents that treat serious and life-threatening
disease states when there is justified clinical data for drug
efficacy. For both nivolumab and pembrolizumab, continued
approval for the treatment of melanoma is still pending additional proof of clinical benefits in various ongoing and future
clinical trials. 4,5
Nivolumab and pembrolizumab are also FDA-approved to
treat patients with metastatic non-small cell lung cancer
(NSCLC) who have experienced disease progression during
or after platinum-based chemotherapy.4,5,11 Nivolumab was
approved in March 2015 for squamous NSCLC, and its indication was further expanded on Oct. 9, 2015, to include
non-squamous NSCLC. 12 Pembrolizumab was approved by
the FDA for advanced NSCLC in October 2015.13 Administration of pembrolizumab for advanced NSCLC requires the use
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of an FDA-approved test to show that the tumor expresses
PD-Ll.5 This diagnostic test, called the PD-Ll IHC 22C3
pharmDx test, is the first tool that is able to detect whether a
non-small cell lung tumor expresses PD-Ll.14
On Nov. 23, 2015, the FDA announced that nivolumab was
approved as a treatment for renal cell carcinoma, the most
common form of kidney cancer in adults.ls Use of nivolumab
for renal cell carcinoma is intended for patients who have
previously received anti-angiogenesis therapy, a type of
treatment that disrupts tumor-mediated formation of new
vasculature. 4·15 Additional clinical trials are ongoing for recruiting patients to study the effectiveness of nivolumab and
pembrolizumab in treating many different cancer types including acute myeloid leukemia, chronic lymphocytic leukemia, glioblastoma and gliosarcoma.16.17 Another anti-PD-1
agent currently being studied, but not yet FDA-approved is
pidilizumab, a humanized monoclonal immunoglobulin Gl
(lgG1) antibody.1a
Mechanism of Action
Nivolumab and pembrolizumab are specific for the human
PD-1 receptor.4,s The monoclonal antibodies bind to PD-1
receptors, mainly located on T-cells, and prevent the receptor from interacting with its ligands, PD-Ll and PD-L2. Since
ligand binding usually functions to inhibit T-cell receptor
signaling and promote tolerance, use of nivolumab or pembrolizumab to block the ligand-receptor interaction results in
increased T-cell receptor signaling. As a result, T-cells are
activated and are able to participate in an anti-tumor immune response to target and kill cancer cells.

For melanoma patients with a BRAF V600 mutation, a BRAF
inhibitor is needed in addition to anti-PD-1 therapy.4,5 BRAF
is a gene that encodes for the protein BRAF, which is involved in the mitogen-activated protein kinase (MAPK) signaling pathway.19 The MAPK pathway is a kinase cascade
needed for regulation of cell growth, proliferation, differentiation and survival. The most common BRAF gene mutation
occurs at codon 600 of the BRAF gene, and results in an amino acid change from a non-polar valine to a polar glutamine
in the BRAF protein. This mutated protein causes the pathway to be constitutively activated, leading to uncontrolled
cell growth and proliferation. BRAF inhibitors, such as vemurafenib, are administered to patients with this mutation in
addition to other antineoplastic therapies.

Literature Review
Pembrolizumab
The KEYNOTE-002 randomized controlled trial compared
pembrolizumab to chemotherapy for ipilumumab-refractory
melanoma.20 The study enrolled 540 patients who had failed
ipilimumab treatment, and randomized them 1:1:1 to 2 mg/
kg every three weeks, 10 mg/kg every three weeks or investigator-choice chemotherapy (paclitaxel plus carboplatin,
paclitaxel, carboplatin, dacarbazine or oral temozolomide).
Patients continued treatment until signs of disease progression were evident. After nine months, 24 percent (95% confidence interval (CI): 17-31) of the pembrolizumab 2 mg/kg
group were progression free, as well 29 percent (22-37) of
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the pembrolizumab 10 mg/kg group. In comparison with the
chemotherapy group, only 8 percent (4-14) were progression free. The pembrolizumab groups also experienced fewer grade 3 to 4 treatment-related adverse effects than the
chemotherapy group. Though limited, the most common adverse effects reported with pembrolizumab were fatigue,
generalized edema, myalgia, hypopituitarism, colitis, diarrhea, decreased appetite, hyponatremia and pneumonitis
(1% each). In the chemotherapy group, the most common
grade 3 to 4 treatment-related adverse effects reported were
anemia (5%), fatigue (5%), neutropenia (4%) and leukopenia (4%). The pembrolizumab groups also showed some improvement in quality of life compared to chemotherapy as
measured from Quality of Life Questionnaire C30 scores from
the European Organization for the Research and Treatment
of Cancer.
The KEYNOTE-006 study, a phase 3 clinical study, examined
the efficacy of pembrolizumab versus ipilimumab in treating
advanced melanoma.21 The 834 patients enrolled were assigned to receive either pembrolizumab 10 mg/kg every two
weeks, pembrolizumab 10 mg/kg every three weeks or four
doses of ipilimumab 3 mg/kg given at three-week intervals.
The overall progression free survival rates were greater for
the pembrolizumab groups than for the ipilimumab group.
The hazard ratio favoring pembrolizumab 10 mg/kg every
two weeks over ipilimumab was 0.58 (95% CI: 0.46-0.72),
and the hazard ratio favoring pembrolizumab 10 mg/kg every three weeks over ipilimumab was 0.58 (0.47-0.72). The
pembrolizumab groups also experienced fewer treatmentrelated adverse effects. Grade 3 to 5 treatment-related adverse effects occurred in 13.3 percent, 10.1 percent, and 19.9
percent in the pembrolizumab every two weeks, pembrolizumab every three weeks and ipilimumab groups, respectively. The most common adverse events reported in the
pembrolizumab groups were fatigue (20.9% and 19.1 % in
the two and three week groups, respectively), diarrhea
(16.9% and 14.4%), rash (14.7% and 13.4%) and pruritus
(14.4% and 14.1%). In the ipilimumab group, the reported
adverse events were pruritus (25.4%), diarrhea (22.7%),
fatigue (15.2%) and rash (14.5%).

Nivolumab
The efficacy of nivolumab in treating refractory squamous
NSCLC was studied in the CheckMate 063 triaJ.22 The investigators wanted to determine nivolumab's effect specifically
for squamous NSCLC because this subtype has a very poor
prognosis, and new potential treatments are often designed
for non-squamous subtypes. Nivolumab 3 mg/kg every two
weeks was administered to 117 patients with stage IIIB or IV
squamous NSCLC until the disease progressed or until patients experienced unacceptable toxic effects. Of the 117 patients, 17 had a confirmed response and 11 showed a tumor
reduction of at least 50 percent. Grade 3 to 4 treatmentrelated adverse events, more commonly fatigue, pneumonitis
and diarrhea, were reported in 17 percent of patients.
Nivolumab was also compared to chemotherapy in patients
with advanced melanoma in the CheckMate 03 7 trial.23 A
total of 405 patients with unresectable stage IIIC or IV meta-
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static melanoma were randomized 2:1 to receive nivolumab
3 mg/kg every two weeks or investigator's choice of chemotherapy (dacarbazine or paclitaxel with carboplatin). The
progression free survival at six months was 48 percent (95%
CI: 38-56) and 34 percent (18-51) in the nivolumab and
chemotherapy groups, respectively. Nine percent of nivolumab patients experienced a treatment-related adverse
event of grade 3 to 4 as compared with 31 percent of the
chemotherapy group. The most common grade 3 to 4 events
reported in the nivolumab group were increased lipase, increased alanine aminotransferase, fatigue and anemia (1 %
each).
New Drugs on the Horizon
In a study conducted by Westin and associates, another monoclonal PD-1 inhibitor, pidilizumab, was examined in combination with the monoclonal ritixumab for treating follicular
lymphoma.24 Patients who had grade 1 to 2 follicular lymphoma and ritixumab-sensitive disease were administered 3
mg/kg of pidilizumab every four weeks for four infusions
and 375 mg/mZ of ritixumab weekly for four weeks, starting
17 days after the first pidilizumab infusion. Of the 29 patients
enrolled, 25 (86%) experienced tumor regression. In addition, no grade 3 to 4 treatment-related adverse effects were
reported. Although pidilizumab showed success in this trial,
it is still awaiting approval from the FDA.
Adverse Drug Events
Adverse drug events commonly associated with PD-1
inhibitors include fatigue, pruritus, decreased appetite and
gastrointestinal disorders. 4·5 The most common side effects
associated with pembrolizumab and nivolumab plus
ipilimumab during treatment of melanoma can be seen in
Table 1.2s.26 Side effects from use of nivolumab in advanced
squamous NSCLC include: cough, nausea, constipation,
fatigue, muscle pain, dyspnea and decreased appetite. 4 Rare
but serious side effects may result in the discontinuation of
pembrolizumab and nivolumab. These side effects include:
grade 3 or 4 pneumonitis, nephritis, infusion-related reactions, a five time increase in baseline AST and ALT levels and
a bilirubin level greater than three times baseline. 4·5
Nivolumab should also be discontinued in patients with signs
of hypophysitis, adrenal insufficiency, life-threatening rash
and encephalitis.4
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Anti-PD-1 drug actions on the immune system can lead to
complications such as immune-mediated hepatitis, colitis,
hypophysitis, nephritis and thyroid disorders. The development of these immune-mediated conditions may warrant the
use of corticosteroids, with therapy ranging from three days
up to 12 weeks.4.s In a phase I cohort study, Weber et al.,
evaluated the safety and tolerability of nivolumab in both
ipilimumab-nalve and -refractory patients. Patients were
started at a 60 mg prednisone dose and were tapered down
to treat grade 3 bilateral optic neuritis, a dose-limiting toxicity. Two patients discontinued treatment of nivolumab due to
high-grade fever and pneumonitis, resulting in a 60 mg and a
120 mg prednisone taper, respectively. Sixty-four patients
were enrolled in the ipilimumab-refractory cohort, and one
patient experienced intense rash, which resolved with a sixweek prednisone taper starting from 60 mg.27
Currently, anti-PD-1 medications are not approved in pregnancy or breast-feeding. Endogenous PD-1 inhibitors are
immunoglobulin IgG4, which crosses the placenta directly
from the mother. 4 Immunoglobulin G (IgG) is the only member of the immunoglobulin class to cross the placenta, and
therefore, is present in high concentration in newborns.2s
This implies that anti-PD-1 medications would also have the
same effect, warranting caution with use in pregnancy. Although pembrolizumab has not undergone clinical animal
reproduction studies with a focus on fetal development,
nivolumab has been evaluated in cynomolgus monkeys.
Nivolumab is currently listed as pregnancy category C and was
found to cause fetal harm, higher incidence of stillbirth, premature delivery, infant mortality and abortion of the fetus.4.S
In recent studies, pembrolizumab has demonstrated a superior safety profile relative to previous chemotherapy treatments for advanced melanoma. A randomized controlled
phase 3 study conducted by Robert et al., compared pembrolizumab and ipilimumab. Overall, ipilimumab was shown
to cause a higher percentage of high-grade adverse events,
which occurred in 19.9 percent of patients. Pembrolizumab
was shown to have a more gradual onset of serious adverse
events compared to ipilimumab. Additionally, the rate of permanent removal from the study was lower in pembroliza
mah-treated patients. 21

Table 1. Anti-PD-1 Agents Most Frequent Adverse Drug Events. 25' 26
Most Frequent Adverse Drug Events

Agent
Pembrolizumab

Fatigue 19.4%

Pruritis 10.7%

Decreased
Appetite 10.5%

Rash 9.7%

Arthralgia 9.1%

Nivolumab plus
lpilimumab

Diarrhea 45%

Rash41%

Fatigue 39%

Pruritis 35%

Colitis 23%

Table 1 totals: obtained from pembrolizumab for non-small-cell lung cancer based on 495 treated patients from Garon et al., and
nivolumab and ipilimumab vs. ipilimumab in untreated melanoma based on 94 patients from Postow et al.
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Cost Implication
A barrier of any new medication, especially monoclonal antibodies, is cost. On average, pembrolizumab will cost $12,500
per cycle of treatment. Treatment can range from two to 12
months, resulting in a cost of over $150,000 for many patients. A year of treatment for nivolumab can reach
$143,000.29 Before the initiation of treatment, patients must
undergo genetic testing as well. The FDA-approved genetic
test known as the Cobas® 4800 test used to detect the
BRAF V600 mutation gene represents an additional cost.30
Pharmacists' Role
Recommendations
As with any new drugs, pharmacists bear the responsibility
as drug experts to understand the drugs well enough to be
able to educate and advise not only patients, but also prescribers on their appropriate use in therapy. The guidelines
provided by the National Comprehensive Cancer Network
(NCCN) are helpful when trying to decide the best course of
treatment for cancers. The following is a summary of NCCN
recommendations that pharmacists may consider during
nivolumab and pembrolizumab therapy in relation to comparable therapies.
According to the NCCN guidelines for the treatment of metastatic or unresectable melanoma, anti-PD-1 monotherapy
(pembrolizumab or nivolumab) is an appropriate first-line
therapy for patients with a BRAF V600 wild-type mutation.11
Alternative first-line therapies for metastatic or unresectable
melanoma include nivolumab/ipilimumab, dabrafenib/
trametinib, vemurafenib or dabrafenib. Nivolumab or pembrolizumab can also be used as second-line therapy in the
case of treatment failure or disease progression after trial
with another first-line treatment, as long as the patient has a
performance status ofO to 2.21
The NCCN NSCLC guidelines state that nivolumab and pembrolizumab can be used as subsequent therapy for patients
with a performance scale of 0 to 2 following a progression of
the disease after first-line therapies have been attempted for
large cell adenocarcinoma and squamous cell carcinoma.11
First-line therapies for NSCLC include doublet chemotherapy, bevacizumab or chemotherapy based on a patient's performance score.
For kidney cancer, nivolumab is also indicated as subsequent
therapy in the treatment of renal cell carcinoma specifically
in the case of disease relapse and stage IV or unresectable
renal carcinoma according to the NCCN guidelines. 31 After
first-line therapy such as participation in a clinical trial,
sunitinub, terrisirolimus, bevacizumab/IFN, pazopanib, high
dose JL-2, axitinib, or sorafenib, nivolumab may be used if a
patient requires follow-up therapy.

Patient Education
Pharmacists should advise patients to contact their
healthcare provider if they experience adverse reactions
such as a fever of 100.4° For higher, difficulty breathing, or if
they exhibit any signs of an allergic reaction such as hives,
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red or blistered skin, swelling of the mouth or tongue or
tightness in the chest. 32 Pharmacists should also inform patients of common side effects such as diarrhea, nausea, vomiting, fatigue and dizziness. For these reasons, patients
should be instructed to drive or operate machinery with
caution during treatment periods. While taking anti-PD-1
medications it is pertinent that patients are aware of the embryonic hazards of these medications, and utilize barrier
methods such as condoms for at least five months after discontinuation. Pharmacists should also encourage patients to
drink plenty of fluids, wash their hands often, eat small frequent meals and rest during treatment with these medications.

Conclusion
The PD-1 pathway plays an important role in the normal
functioning of the immune system. This pathway also presents a means of treatment against cancer cells expressing
the PD-1 ligands, especially in tumors that fail to fully respond to traditional treatments. Monoclonal antibodies directed against the PD-1 receptor are able to elicit an immune
response against such cells. Anti-PD-1 drugs, nivolumab
(Opdivo®) and pembrolizumab (Keytruda®), were granted
accelerated approval by the FDA. Both drugs are indicated in
treatment of advanced melanoma and NSCLC, as well as tumors refractory to treatment that have BRAF mutations. Trials are ongoing to determine long-term efficacy of these
agents, as well as exploring additional cancer types. Further
research into anti-PD-1 drugs has already produced at least
one new member of this class, which shows promising results in early clinical trials. As more trial data becomes available, and nivolumab and pembrolizumab continue to receive
FDA approval for new indications, pharmacists in all practice
settings should be aware of the appropriate use and adverse
effects of anti-PD-1 drugs.
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